Current treatments do not cure individuals of HIV because of HIV's ability to persist as provirus within long-lived immune cells, especially memory T cells. Most attempts to clear these reservoirs have involved the destruction of latently infected cells, and such efforts to date have been unsuccessful. A more elegant solution to the problem of HIV infection would be the ability to eliminate or otherwise disable integrated HIV without inducing death of infected cells. We have recently begun to evaluate a novel approach to achieve this, via the use of novel, highly specific enzymes known as homing endonucleases (HEs). HEs are proteins that specifically target long (~20 base pair) sequences in double stranded DNA. The long recognition sites ensure high specificity and prevent off-target effects. Upon recognition of their target sites, HEs induce DNA double strand breaks (dsb) at the sites, which in mammalian cells are most commonly repaired via non-homologous end joining (NHEJ). NHEJ repair is error prone, and can lead to mutation typically resulting in deletions surrounding the cleavage site ranging from 1 base to several kilobases. In our preliminary studies, we created an engineered reporter virus containing the recognition site for the natural HE l-Anil, to demonstrate that integrated provirus can be successfully targeted for attack, cleavage, and mutagenesis by HEs. Based on this success, we have now assembled a team of investigators with the complementary expertise necessary to rationally redesign natural homing endonucleases such that they will recognize conserved sequences within SHIV.
Our aims are as follows. 1) Design variant homing endonucleases targeting integrated SHIV sequences. We will build upon existing collaborations with Drs. David Baker and Andrew Scharenberg, with whom we have already used computational and bacterial selection approaches to design novel HEs recognizing conserved sequences from HIV. 2) Optimize the DNA-modifying efficacy of SHIV-specific homing endonucleases. We will do this by directed evolution processes for selection of increased activity, and by linking the HEs to TREX2, which we have shown increases the incidence of targeted mutation. 3) Establish the optimal methods for delivery of SHIV-specific HEs to macaque CD4+ T cells and CD34+ stem cells, and determine the ability of HEs to clear viable provirus from these reservoirs. During autologous hematopoietic stem cell transplantation in HIV-infected individuals, between 10[5] and 10[10] copies of HIV provirus are re-infused along with the graft, and the ability to purge viable virus from these cells before reintroduction may be of clinical benefit to the patient.

Public Health Relevance

The long-term goal of this project is to use novel, highly specific enzymes known as homing endonucleases to achieve virologic cure of HIV, by targeting and mutating the integrated HIV such that it is rendered incapable of further replication and pathogenesis. The results would offer the possibility of cure for individuals infected with HIV.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI096111-03
Application #
8497604
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
3
Fiscal Year
2013
Total Cost
$590,756
Indirect Cost
$79,650
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Peterson, Christopher W; Wang, Jianbin; Norman, Krystin K et al. (2016) Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates. Blood 127:2416-26
Sedlak, Ruth Hall; Liang, Shu; Niyonzima, Nixon et al. (2016) Digital detection of endonuclease mediated gene disruption in the HIV provirus. Sci Rep 6:20064
Dimitrov, Dobromir T; Kiem, Hans-Peter; Jerome, Keith R et al. (2016) A curative regimen would decrease HIV prevalence but not HIV incidence unless targeted to an ART-naïve population. Sci Rep 6:22183
Stone, Daniel; Niyonzima, Nixon; Jerome, Keith R (2016) Genome editing and the next generation of antiviral therapy. Hum Genet 135:1071-82
Spragg, Chelsea; De Silva Feelixge, Harshana; Jerome, Keith R (2016) Cell and gene therapy strategies to eradicate HIV reservoirs. Curr Opin HIV AIDS 11:442-9
Romano Ibarra, Guillermo S; Paul, Biswajit; Sather, Blythe D et al. (2016) Efficient Modification of the CCR5 Locus in Primary Human T Cells With megaTAL Nuclease Establishes HIV-1 Resistance. Mol Ther Nucleic Acids 5:e352
Johnston, Christine; Harrington, Robert; Jain, Rupali et al. (2016) Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant 22:149-56
De Silva Feelixge, Harshana S; Stone, Daniel; Pietz, Harlan L et al. (2016) Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. Antiviral Res 126:90-8
Peterson, Christopher W; Haworth, Kevin G; Burke, Bryan P et al. (2016) Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS. Mol Ther Methods Clin Dev 3:16007
Adair, Jennifer E; Waters, Timothy; Haworth, Kevin G et al. (2016) Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy. Nat Commun 7:13173

Showing the most recent 10 out of 44 publications